U.S. markets closed

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, March 16, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. 

1. Details of the person discharging managerial responsibilities/person closely associated  
a) Name Henrik Juuel
2. Reason for the notification
a) Position/status

 
Executive Vice President and Chief Financial Officer of Bavarian Nordic A/S
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Bavarian Nordic A/S
b) LEI 2138006JCDVYIN6INP51
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument


Identification code
New shares


DK0061268711
b) Nature of the transaction Purchase (exercise of subscription rights)
c) Price(s) and volume(s) Price(s) Volume(s)
    DKK 109 2,500
d) Aggregated information
  • Aggregated volume
  • Price
 

2,500
DKK 272,500.00
e) Date of the transaction 2020-03-16
f) Place of the transaction Nasdaq Copenhagen A/S, XCSE


1. Details of the person discharging managerial responsibilities/person closely associated  
a) Name Henrik Juuel
2. Reason for the notification
a) Position/status

 
Executive Vice President and Chief Financial Officer of Bavarian Nordic A/S
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Bavarian Nordic A/S
b) LEI 2138006JCDVYIN6INP51
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument


Identification code
Subscription rights


DK0061268638
b) Nature of the transaction Purchase of subscription rights
c) Price(s) and volume(s) Price(s) Volume(s)
    DKK 1.68 2,500
d) Aggregated information
  • Aggregated volume
  • Price
 

2,500
DKK 4,200.00
e) Date of the transaction 2020-03-16
f) Place of the transaction Nasdaq Copenhagen A/S, XCSE


1. Details of the person discharging managerial responsibilities/person closely associated  
a) Name Paul Chaplin
2. Reason for the notification
a) Position/status

 
President and Chief Executive Officer of Bavarian Nordic A/S
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Bavarian Nordic A/S
b) LEI 2138006JCDVYIN6INP51
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument


Identification code
New shares


DK0061268711
b) Nature of the transaction Purchase (exercise of subscription rights)
c) Price(s) and volume(s) Price(s) Volume(s)
    DKK 109 25,534
d) Aggregated information
  • Aggregated volume
  • Price
 

25,534
DKK 2,783,206.00
e) Date of the transaction 2020-03-11
f) Place of the transaction Nasdaq Copenhagen A/S, XCSE


1. Details of the person discharging managerial responsibilities/person closely associated  
a) Name Paul Chaplin
2. Reason for the notification
a) Position/status

 
President and Chief Executive Officer of Bavarian Nordic A/S
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Bavarian Nordic A/S
b) LEI 2138006JCDVYIN6INP51
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument


Identification code
Subscription rights


DK0061268638
b) Nature of the transaction Sale of subscription rights
c) Price(s) and volume(s) Price(s) Volume(s)
    DKK 9.85 130,514
d) Aggregated information
  • Aggregated volume
  • Price
 

130,514
DKK 1,285,199.17
e) Date of the transaction 2020-03-11
f) Place of the transaction Nasdaq Copenhagen A/S, XCSE


1. Details of the person discharging managerial responsibilities/person closely associated  
a) Name Paul Chaplin
2. Reason for the notification
a) Position/status

 
President and Chief Executive Officer of Bavarian Nordic A/S
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Bavarian Nordic A/S
b) LEI 2138006JCDVYIN6INP51
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument


Identification code
Shares


DK0015998017
b) Nature of the transaction Acquisition of shares (vesting of restricted stock units)
c) Price(s) and volume(s) Price(s) Volume(s)
    DKK 194.90 4,971
d) Aggregated information
  • Aggregated volume
  • Price
 

4,971
DKK 968,870.00
e) Date of the transaction 2020-03-16
f) Place of the transaction Outside a trading venue

About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and has been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an investigational Ebola vaccine, licensed to Janssen. For more information visit www.bavarian-nordic.com.

Contacts
Rolf Sass Sørensen
Vice President Investor Relations (EU)
Tel: +45 61 77 47 43

Graham Morrell
Paddock Circle Advisors (US)
graham@paddockcircle.com
Tel: +1 781 686 9600

Company Announcement no. 11 / 2020

Attachment